After a rocky two years, money has started flowing back to biotech, with the return of the megaround exemplified in the $1 billion fundraise of 2024’s top moneymaker, Xaira Therapeutics.…
New analysis identifies private equity investment trends in the industry and how a changing environment could spur an increased pace. KEY TAKEAWAYS Healthcare deals by private equity firms in 2024…
Biomarkers such as ribonucleic acid (RNA), deoxyribonucleic acid (DNA), proteins, lipids and other biomolecules are playing an increasingly vital role in advancing our understanding of health, driving drug development and improving clinical trial…
Chinese drug maker Akeso, whose new cancer drug has outperformed a leading Western peer in clinical studies, is being hailed as the "DeepSeek moment" for China's drug industry, as biotech…
05.01.24 | news HiberCell Announces First Patient Dosed in Clinical Collaboration with Merck, Evaluating HC-7366 in Combination with WELIREG® (belzutifan) in patients with advanced ccRCC BOSTON, May 01, 2024 (GLOBE NEWSWIRE) —…
Arch Venture Partners has backed the three largest private biotech financings so far in 2024. (niphon/iStock/Getty Images Plus) The three highest private biotech financings so far in 2024 totaled nearly $1.7…